3-deazaneplanocin has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Liang, C; Liu, C; Ren, X; Tian, L; Xia, J | 1 |
| Cartron, G; Cavalli, G; Herviou, L; Klein, B; Moreaux, J | 1 |
2 review(s) available for 3-deazaneplanocin and Hematologic Malignancies
| Article | Year |
|---|---|
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Topics: Animals; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Hematologic Neoplasms; Histone Methyltransferases; Humans; Molecular Targeted Therapy; Neoplasms; Structure-Activity Relationship | 2022 |
EZH2 in normal hematopoiesis and hematological malignancies.
Topics: Adenosine; B-Lymphocytes; Cell Differentiation; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Ethylenediamines; Gene Expression Regulation; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cells; Histones; Humans; Indoles; Methylation; Polycomb Repressive Complex 2; Precision Medicine; Pyrazoles; Pyridones | 2016 |